Loteprednol Etabonate Suspension/ Drops
NDC Package 72603-324-02
Package Information
Loteprednol Etabonate suspension/ dropses is loteprednol etabonate ophthalmic suspension is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation.Loteprednol etabonate ophthalmic suspension is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with loteprednol etabonate ophthalmic suspension experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. This formulation utilizes a suspension/ drops delivery system. Marketed by Northstar Rxllc, this product is identified by NDC 72603-324 and is authorized under FDA application ANDA212450.
Identification & Billing
- RxCUI: 311382 - loteprednol etabonate 0.5 % Ophthalmic Suspension
- RxCUI: 311382 - loteprednol etabonate 5 MG/ML Ophthalmic Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 72603 - Northstar Rxllc
- 72603-324 - Loteprednol Etabonate
- 72603-324-02 - 1 BOTTLE in 1 CARTON / 10 mL in 1 BOTTLE
- 72603-324 - Loteprednol Etabonate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (72603-324). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 72603-324-02 identifies a specific commercial package of 1 bottle in 1 carton / 10 ml in 1 bottle of Loteprednol Etabonate, a human prescription drug labeled by Northstar Rxllc. This suspension/ drops is formulated for ophthalmic use and contains loteprednol etabonate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Northstar Rxllc on September 01, 2024.
How is this Northstar Rxllc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 72603032402. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.